North American margins drove the beat, yet the automaker lowered net income guidance for a second straight quarter.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Investing.com -- The clash between pharma titans Novo Nordisk and Eli Lilly just escalated from the pharmacy counter to the courtroom. Novo Nordisk Inc. filed a lawsuit in the U.S. District Court for the District of New Jersey against Eli Lilly and Company and Lilly USA, LLC, alleging multiple violations of federal and state false advertising and unfair competition laws under the Lanham Act. The lawsuit takes aim at Lillyâs aggressive direct-to-consumer (DTC) advertising campaigns for its blockb
Microchip Technology is scheduled to post its first-quarter results soon, and analysts predict a triple-digit surge in the companyâs bottom-line figure.
Two industrial giants report Q2 results on the same day, and analysts are anything but neutral between them. Before you decide which earnings announcement to watch on July 22, you need to see how these two stack up across every dimension Wall Street actually measures.
Vicor (VICR) delivered earnings and revenue surprises of +67.74% and +3.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Ozempic maker Novo Nordisk has filed a lawsuit against Eli Lilly, arguing it uses deceptive advertising to mislead consumers. The complaint accuses Eli Lilly of using outdated studies to promote its branded GLP-1 drugs, Mounjaro and Zepbound, as helping consumers lose significantly more weight on average than Novo Nordiskâs Ozempic and Wegovy.
Investing.com -- Northrop Grumman Corporation (NYSE: NOC) reported second-quarter earnings on Tuesday ahead of the open, topping analyst expectations, with the company also raising its full-year guidance.
Memory chip shortages continue to be a problem for most companies.
Halliburton logged higher earnings and revenue in the second quarter thanks to gains in both its North American and overseas markets.
The first components of an ASML next-generation chipmaking tool arrived âat New York state's Albany NanoTech Complex on âTuesday, the governor's office said. The NanoTech complex will use the tool to conduct âresearch and development on future forms of chip design and manufacturing. The NanoTech facility is the only one of its kind in North America, according to NY Creates Director Dave Anderson, and âis similar in â scope and focus to Europe's Imec, which operates in Belgium.
SpaceXâs IPO was the biggest in history, raising $75 billion at $135 a share.1 The offering sparked much excitement, with retail investors keen on buying into one of the worldâs most closely watched companies. If you had invested $2,000 at the $135 IPO price, hereâs how much your investment would be worth today, and why [âŚ] The post If You Invested $2K in the SpaceX IPO, How Much Do You Have Now? appeared first on SmartReads by SmartAsset.
The maker of Ozempic and Wegovy says its competitor is misleading consumers by citing outdated weight-loss data in advertisements.
The maker of Ozempic and Wegovy says its competitor is misleading consumers by citing outdated weight-loss data in advertisements.
(Bloomberg) -- Strong economic momentum is a double-edged sword for US equity traders. Solid growth is an earnings tailwind. But let it run too hot, and it turns from blessing to curse.Most Read from BloombergYemenâs Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshotâs Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshotâs Kimi K3 May Be More About Memory Than ComputeUS Strikes Iran in Escalating Campaign After Troops K
đŁ âWhen I look at AI itself, the amount of money being spent is huge. Will it in total pay off? Probably, just like the internet did. Will it pay off the way you expect on the timetable you expect? Definitely not.
By Maggie Fick LONDON, July 21 (Reuters) - Novo Nordisk said on Tuesday it was suing rival Eli Lilly in U.S. federal court, accusing the U.S. drugmaker of false advertising in claiming its weight-loss
A trading boom that carried most of Wall Street to record results this spring also lifted Charles Schwabâs quarterly profits by 32%. The brokerage reported second-quarter net income of $2.8 billion on Tuesday.
(Bloomberg) -- One of the most enduring foreign-exchange bets is off to its best run in decades as surprisingly muted volatility across asset classes has investors piling into carry trades.Most Read from BloombergYemenâs Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshotâs Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshotâs Kimi K3 May Be More About Memory Than ComputeUS Strikes Iran in Escalating Campaign After Troo
(Bloomberg) -- Novo Nordisk A/S is suing Eli Lilly & Co. in US federal court, claiming that Lillyâs advertising for its blockbuster obesity shot Zepbound and diabetes injection Mounjaro is misleading as competition between the two drugmakers escalates.Most Read from BloombergYemenâs Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshotâs Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshotâs Kimi K3 May Be More About Memor
General Motors (GM) delivered earnings and revenue surprises of +14.06% and +3.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
(Bloomberg) -- Charles Schwab Corp. reported earnings that topped estimates as retail investors continued to jump in and out of the market amid volatility sparked by geopolitical uncertainty.Most Read from BloombergYemenâs Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshotâs Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshotâs Kimi K3 May Be More About Memory Than ComputeUS Strikes Iran in Escalating Campaign After Tr
General Motors posted second-quarter net income of $1.31 billion, or $1.41 a share, with revenue rising to $48.03 billion.
Under the deal, Personalisâ minimal residual disease (MRD) test will be integrated into Tempusâ broader oncology portfolio.
The aerospace and defense company posted a profit of $1.09 billion, or $7.68 a share in the second quarter, with sales up 5% at $10.88 billion.
Novo Nordisk has accused arch-rival Eli Lilly of peddling false claims about its weight-loss products in advertising campaigns, marking the latest...
Texas Instruments and ServiceNow both report earnings on the same day after weeks of steep selloffs, and Wall Street is quietly stacking its chips heavily toward one of them while the other faces a very different kind of pressure.
Halliburton stock declines after the oilfield services company posts slightly better-than-expected earnings but sees the war in the Middle East take its toll on business.
Micron stock and SK Hynix were rising ahead of Big Tech earnings but there is a risk that big customers will look to sidestep soaring memory costs.